CLCéline Louapre

Céline Louapre

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Céline Louapre has a total of 344 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Multiple Sclerosis Relapses Are Associated With EBV-Specific T-Cell Expansion Amid Broad Immune Activation

    by Leslie Adda, Hélène Vantomme, Vanessa Mhanna, Paul Stys, Pierre Barennes, Charline Jouannet, Nicolas Coatnoan, Vimala Diderot, Johanna Dubois, Celine Louapre, et al.

  • Air pollution and the risk of multiple sclerosis relapses in the Paris region, the CONFISEP study

    by Edouard Januel, Caroline Papeix, Alexia Baudic, Basile Chaix, Elisabeth Maillart, Céline Louapre, Thomas Roux, Amelie Yavchitz, Caroline Bensa-Koscher, Romain Deschamps, et al.

    Background Air pollution has been proposed as a short-term trigger of multiple sclerosis (MS) relapses, but delayed effects remain poorly studied in the era of modern disease-modifying therapies (DMTs). We investigated whether weekly air pollution exposure was associated with delayed MS relapse risk up to 15 weeks. Methods We conducted a bicentric retrospective cohort study in the Île-de-France region (2018–2021) including adults with relapsing MS from the Observatoire Français de la Sclérose en Plaques registry. Weekly exposure to particulate matter (PM)10, PM2.5, nitrogen dioxide (NO2) and ozone (O3) was estimated using Airparif street-level modelling data. Associations (lags 0–15 weeks) were assessed using self-controlled case series and cohort analyses adjusted for time-varying DMTs, disease duration, number of relapses during the previous year, respiratory infections, temperature, sunlight exposure, lockdown and holiday periods and additionally for age, sex, deprivation index and urbanicity in cohort analyses. Results Among 1152 patients (73.6% women; median age 37 years), 898 relapses occurred (0.20/patient-year). In self-controlled analyses, PM10 exposure was associated with increased relapse risk at 2-week (incidence rate ratio (IRR) 1.28, 95% CI 1.05 to 1.57) and 11-week lags (IRR 1.26, 95% CI 1.02 to 1.54), PM2.5 exposure was associated with increased risk at 2-week (IRR 1.20, 95% CI 1.03 to 1.39), while NO2 exposure was associated with increased risk at 2-week (IRR 1.21, 95% CI 1.02 to 1.44), 3-week (IRR 1.26, 95% CI 1.04–1.52) and 12-week lags (IRR 1.32, 95% CI 1.12 to 1.56). Cohort analyses showed similar but weaker associations for PM10 and PM2.5. DMTs were strongly associated with lower relapse risk, with effect sizes greater than those observed for air pollution exposure. Conclusions Weekly exposure to PM10, PM2.5 and NO2 was associated with increased MS relapse risk over delayed time windows ranging from 2– 3 weeks to 11–12 weeks. These temporal windows should be considered exploratory given the multiple lag-specific analyses. DMTs remained the strongest determinants of relapse risk. Trial registration number NCT05033782.

  • Open Access

    Optic Neuritis Model to Identify Potential Neuroprotective Therapy

    by Mark J. Kupersmith, Wolf A. Lagrèze, Jeffrey L. Bennett, Louise-Laure Mariani, Céline Louapre, Leonard A. Levin

    Was not provided for this article.

  • Open Access

    Drivers of Rising Prevalence in Major Motor Neurodegenerative Diseases

    by Octave Guinebretiere, Fen Yang, Dang Wei, Quentin Calonge, Yihan Hu, Karin Wirdefeldt, Caroline Ingre, Fredrik Piehl, Karin Modig, Weimin Ye, et al.

    The prevalence of Parkinson disease (PD), multiple sclerosis (MS), and motor neuron diseases (MNDs) is rising globally. However, it is unclear to what degree this is related to an increase in incidence or to improved survival after diagnosis. We performed 2 nationwide, population-based, retrospective cohort studies, including all individuals living in Sweden between 2001 and 2016 and living in France between 2009 and 2022, respectively. Pooled mixed-effects regression models, with country as a random effect, were used to determine temporal trends in prevalence, crude and age-standardized and sex-standardized incidence, and age and life expectancy at diagnosis. Annualized prevalence of PD, MS, and MNDs increased significantly between 2003 and 2022 in the pooled model (PD: prevalence ratio [PR] per year = 1.014, p < 0.001; MS: PR = 1.029, p < 0.001; MND: PR = 1.028, p < 0.001). While the crude incidence of both PD and MS remained nearly stable over time (PD: incidence rate ratio [IRR] per year = 0.998, p < 0.001; MS: IRR = 0.992, p < 0.001), the standardized incidence showed a more marked decrease for PD (IRR = 0.986, p < 0.001) while remaining almost unchanged for MS (IRR = 0.995, p < 0.001). For MNDs, both the crude and standardized incidence increased over time (crude IRR = 1.018, p < 0.001; standardized IRR = 1.008, p < 0.001). Life expectancy at diagnosis of PD increased between 2003 and 2013 (+0.95 months per calendar year, p < 0.001) and then decreased between 2013 and 2022 (−1.20 months, p = 0.002), while it increased significantly over the entire study period for MS (+2.35 months, p < 0.001) and MNDs (+0.34 months, p = 0.01). These findings indicate that the rising MS prevalence is largely survival-driven and the rising MND prevalence reflects a true increase in incidence, whereas PD prevalence grows modestly, largely independent of incidence. Depending on the mechanism that drives prevalence, whether increased incidence reflecting changing risk factor exposures, improved survival due to therapeutic advances, or demographic aging of the population, inferences about underlying causes differ substantially between PD, MS, and MNDs, with direct implications for health care planning and etiologic research.


  • Open Access

    Neurological Manifestations of Mycoplasma pneumoniae Infection in Hospitalized Adults During the 2023–2024 French Epidemic, Clinical Characterization and Comparative Outcomes: A Multicenter Study

    by Matthieu Holub, Ariane Gavaud, Céline Louapre, Alexandre Bleibtreu, Morgane Mailhe, Francois Goehringer, Gwenael Le Moal, Louis Bohard, Anne Sophie Lecompte, Marine Avenel, et al.

    Background: Mycoplasma pneumoniae (MP) primarily causes respiratory infections but can lead to neurological manifestations. This study aimed to characterize these manifestations in adults during an epidemic. Methods: The national MYCADO cohort included 1309 adults hospitalized with MP infection during the 2023–2024 French epidemic. An ancillary study identified and described MP-related central (CNS) and peripheral (PNS) nervous system manifestations. Data were retrospectively extracted from medical records, with clinical follow-up up to 3 months after discharge. Results: Twenty-eight patients with neurological manifestations attributable to MP were identified (2.1% of the cohort). Of these, 19 affected the CNS, including encephalitis (n = 8), myelitis (n = 3), encephalo-myelitis (n = 2), isolated meningitis (n = 6), and cerebral vasculitis (n = 1). Nine involved the PNS: Guillain-Barré syndrome (n = 6), peripheral polyneuropathy (n = 2), and multifocal neuropathy (n = 1). The median age (interquartile range) was 35 years (29–49) years; 60.7% were men. Neurological symptoms appeared a median of 7 days after MP infection onset. Nearly half (46.4%, n = 13) required intensive care; neurological failure was the leading cause of intensive care unit transfer (12/13, 92.3%). Compared with MP patients without neurological manifestations, those with neurological involvement had longer hospital stays (13 vs 9 days; P < .001), more frequent invasive mechanical ventilation (35.7% vs 4.2%; P < .001), and more rehabilitation transfers (42.8% vs 4.3%; P < .001). At discharge, neurological sequelae were present in 47.3% of CNS patients and all Guillain-Barré syndrome (GBS) patients. At 3 months, sequelae persisted in 36.8% of CNS patients and all GBS patients. Conclusions: In adults, MP infection causes rare but diverse and frequently severe neurological manifestations that worsen clinical course and result in long-term disability.

  • Open Access

    Magnetoencephalography biomarkers for assessing myelin content and neuronal function in acute optic neuritis

    by Ysoline Beigneux, Christophe Gitton, Abdul Rauf Anwar, Jean-Didier Lemarechal, Mariem Hamzaoui, Michel Paques, Catherine Vignal, Isabelle Audo, Benedetta Bodini, Bruno Stankoff, et al.

    The visual pathway is an important model system for remyelination and neuroprotection trials in multiple sclerosis, due to its accessibility and the availability of validated methods including visual evoked potential and optical coherence tomography. However, visual evoked potentials are sometimes undetectable and demonstrate limited reliability after acute optic neuritis. This study aims to investigate novel magnetoencephalography markers for assessing myelin content and neuronal dysfunction in the early phase of optic neuritis and describes their inter-run reproducibility (‘over a single visit’) and association with short-term visual outcomes. Patients with unilateral acute optic neuritis were recruited and underwent ophthalmological assessments, brain MRI and magnetoencephalography. Magnetoencephalography data were acquired during visual stimulation with an alternating checkerboard pattern. We used source localization to reconstruct brain activity in the primary visual cortex (V1) and analysed it in the temporal and frequency domains. In the temporal domain, we focused on M100 latency—the magnetic counterpart of P100 latency. In the frequency domain, we assessed the spectral richness of the steady-state evoked field response by harmonic count, which reflects the diversity of frequency components present in the brain signal. Thirty-two patients were included at a median of 54 days [interquartile range = (37.5–78)] post-symptom onset of optic neuritis. Among patients with optic neuritis, visual evoked field recordings were detectable in 77% of cases, compared with 66% for visual evoked potential recordings. M100 latency demonstrated an excellent inter-run reproducibility for both fellow and affected eyes [intra-class correlation coefficient (ICC) >0.8, mean absolute inter-run difference of 2.99 ± 6.53 and 3.76 ± 7.53 ms, respectively]. By comparison, the reproducibility of P100 latency was good for fellow eye (ICC = 0.7, mean absolute inter-run difference of 3.9 ± 6.2 ms) but moderate for affected eye (ICC = 0.6, mean absolute inter-run difference of 9.1 ± 21.8 ms). In the frequency domain, the harmonic count correlated strongly with ganglion cell layer volume (r = 0.68, P = 0.0001), likely reflecting functional consequences of neuronal loss. Measures reflecting demyelination (P100 and M100 latencies) correlated with measures of neuronal damage (ganglion cell layer volume and harmonic count) from both conventional and magnetoencephalography assessments. Visual impairment was associated with neuronal damage (parameter estimates: β = 0.49, P = 0.017 for ganglion cell layer volume, β = 0.57, P = 0.003 for harmonic count) but not with demyelination measures. Our results highlight magnetoencephalography as a reproducible and comprehensive tool to study both myelin content and neuronal dysfunction shortly after optic neuritis and suggest that, at this early stage, neuronal damage is already the main driver of visual outcome.

  • Open Access

    Remyelination and neuroprotection translational trials: Lessons from optic neuritis

    by C. Louapre, Y. Beigneux, F. Maestri, C. Meyniel, V. Touitou

  • Corrélats structuraux et fonctionnels de l'atteinte cognitive précoce au cours de la sclérose en plaques

    by Céline Louapre

    Des troubles cognitifs sévères peuvent apparaître de façon précoce au cours de la sclérose en plaques(SEP). Nous avons analysé les modifications de connectivité fonctionnelle de repos au sein des réseauxcérébraux et les modifications structurelles cérébrales qui les sous-tendent.Nous avons inclus des patients atteints de SEP dont la durée de la maladie est comprise entre 3 et 5ans, sans trouble cognitif (n=20) et avec un trouble cognitif (n=15) ainsi que des sujets contrôles(n=20). Après une évaluation neuropsychologique approfondie, les patients et contrôles ont eu uneIRM multimodalité à 3T comportant des séquences anatomiques T1 et T2, une séquence en tenseur dediffusion pour l’évaluation de la connectivité anatomique, et une IRM fonctionnelle de repos pourl’évaluation de la connectivité fonctionnelle.Les patients avec atteinte cognitive ont des performances diminuées pour l’ensemble des domainesneuropsychologiques testés en dehors du stockage mnésique. La connectivité fonctionnelle est altéréechez les patients avec atteinte cognitive au sein des réseaux impliqués dans les processus cognitifscomme le réseau du mode par défaut et les réseaux attentionnels. Ces modifications fonctionnelles nereflètent pas de façon stricte la connectivité anatomique évaluée par l’IRM de diffusion. En revanche,les patients avec atteinte cognitive ont une atrophie marquée de la SG dans des régions connectées auréseau du mode par défaut.La diminution de connectivité fonctionnelle au sein des réseaux impliqués dans la cognition pourraitlimiter les mécanismes de compensation fonctionnelle en réponse à l’atteinte structurelle cérébrale.

  • Open Access

    Clinical relevance and predictors of anti-natalizumab antibodies in multiple sclerosis: A real-world retrospective cohort study

    by Michael Levy, Ysoline Beigneux, Thomas Roux, Mathieu Mossad, Vito Ricigliano, Marie Senant, Caroline Papeix, Bruno Stankoff, Celine Louapre, Elisabeth Maillart, et al.

    Background: Natalizumab is effective for relapsing MS but may trigger anti-natalizumab antibodies (ANZ) that neutralise drug activity and increase reactions. Trials report persistent antibodies in ∼6% and overall prevalence between 4% and 14%, but real-world burden and optimal testing remain uncertain. We assessed ANZ prevalence, timing, and correlates, comparing systematic with indication-driven testing. Methods: Single-centre retrospective cohort of natalizumab-treated patients with ≥1 ANZ test. Testing followed routine care: systematic screening at months 6/12/18 or testing triggered by suspected inefficacy or infusion reactions. Clinical/MRI data were abstracted; time to positivity was used in Kaplan–Meier; predictors were assessed using multivariable logistic regression. Results: Among 182 patients (348 tests), ANZ were detected in nine (4.9%; four persistent and five transient), all within the first 12 infusions. Positivity differed by indication ( p = 0.005): suspected inefficacy 10.5% (4/38), systematic screening 1.6% (5/304), post-reaction testing 0% (0/6). Within suspected inefficacy, MRI activity was more strongly associated with positivity than symptoms alone ( p = 0.04). In multivariable models, suspected inefficacy was the only independent predictor; adding indication improved discrimination (AUC 0.74 vs. 0.56). Conclusions: In routine care, ANZ positivity is uncommon and occurs early. Indication-driven testing – especially when prompted by new MRI lesions – yields greater diagnostic value than routine screening of clinically stable patients, supporting a selective, context-driven approach to ANZ monitoring.